TransMedics Group (TMDX) Earnings Date & Reports

Key Takeaways

• TransMedics Group reported third quarter 2026 revenue of $203 million, up 41% year over year (YoY) and its highest quarterly revenue on record, topping analyst expectations.
• Non-GAAP (adjusted) earnings per share (EPS) came in at $0.51, well above the consensus estimate, while GAAP (generally accepted accounting principles) diluted EPS was $0.46.
• Management raised full-year 2026 revenue guidance to $764 million–$774 million, implying roughly 26%–28% growth over 2025.
• Gross margin dipped to 58.5% as lower-margin service revenue and the newly acquired PAD Aviation business grew faster than product sales.
• Investors can find more on the company's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to see how AI-driven trading tools are identifying market opportunities.

Earnings Context and Why It Matters

TransMedics Group, a medical technology company known for its Organ Care System (OCS) and National OCS Program (NOP), has become a closely watched growth story in the transplant market. The company's third quarter 2026 results matter because they show whether its high-growth model can sustain momentum while it simultaneously pours money into clinical trials, a next-generation OCS platform, and international expansion. Coming into the report, TransMedics had already delivered several consecutive quarters of strong revenue gains, but investors were increasingly focused on rising operating expenses and a shifting revenue mix. The quarter offered a direct test of whether top-line momentum could coexist with heavier strategic investment, making it a key checkpoint for both growth and margin expectations.

Reported Results

TransMedics reported third quarter 2026 revenue of approximately $203 million, up 41% year over year and the strongest quarter in company history. Organic revenue, which excludes the contribution from its PAD Aviation acquisition, grew 35% to about $194 million. Product revenue rose 29% to roughly $113 million, while service revenue jumped 60% to about $90 million. U.S. transplant revenue climbed 34% to approximately $186 million, led by liver cases, and international revenue surged 82% to about $6.6 million.

On the bottom line, non-GAAP (adjusted) EPS reached $0.51, beating consensus estimates, while GAAP diluted EPS was $0.46, down from $0.66 a year earlier. Gross margin came in at 58.5%, down about 40 basis points (a basis point is one-hundredth of a percentage point) year over year, as lower-margin service revenue grew to 44% of total sales. Excluding PAD Aviation, gross margin was 61.1%. Management raised full-year 2026 revenue guidance to a range of $764 million to $774 million, including roughly $14 million from PAD Aviation.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors tracking names like TransMedics Group across the medical technology space, the AI Screener offers a practical way to monitor momentum and compare opportunities within a broader market context.

Market Reaction and Investor Sentiment

Shares of TransMedics Group moved higher in after-hours trading following the release, as the revenue beat and raised full-year guidance outweighed concerns about the quarter's margin mix. The rally offered a measure of relief after a difficult stretch for the stock, which had fallen sharply through 2026 alongside broader investor unease about rising research and development (R&D) spending, clinical trial costs, and the integration of PAD Aviation. Sentiment remained split: bulls pointed to record revenue and accelerating service growth, while more cautious investors focused on the growing share of lower-margin service revenue and the dilution of gross margin from the new aviation business. The raised guidance signaled management's confidence that strong demand would persist into year-end.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether TransMedics can convert its record top-line growth into sustained profitability as it continues investing for the next phase of expansion. The company is ramping up spending on its OCS Kidney program, the next-generation OCS platform, and its ENHANCE heart and De Novo lung clinical trials, all of which are expected to weigh on near-term margins even as they build a foundation for future growth.

International expansion is another key theme. Management is building out its NOP model in Europe, beginning with a program in Italy, and continues to integrate PAD Aviation into its logistics network. The mix of product versus service revenue will remain an important margin driver to monitor, since service revenue carries lower margins than product sales.

Finally, investors should track the company's progress toward its updated full-year 2026 revenue target of $764 million to $774 million, any updates on clinical trial enrollment, and how efficiently management scales its aircraft fleet and logistics operations. These factors will help determine whether TransMedics can maintain its growth trajectory while gradually expanding profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations